Ajanta Pharma promoter releases pledge on 160,000 shares

What Ajanta Pharma announced

Ajanta Pharma Ltd (BSE: 532331, NSE: AJANTPHARM) disclosed that its promoter, the Ravi Agrawal Trust, has released a pledge on 160,000 equity shares of the company. The filing, submitted to both BSE and NSE on 1 July 2026, cites Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The release was effected on 30 June 2026 and is described as being driven by an “excess pledge” situation.

Details of the pledge release

• Promoter involved: Ravi Agrawal, acting as trustee of the Ravi Agrawal Trust.
• Number of shares released: 160,000 shares, equivalent to 0.13% of Ajanta Pharma’s total share capital.
• Previous pledged amount: 1,697,696 shares (10.24% of total share capital) were pledged before the release.
• Post‑release pledged amount: 1,537,696 shares (1.23% of total share capital) remain pledged.
• Lender: Infina Finance Private Limited, with Barclays Securities (India) Private Limited acting as depository participant.
• Reason for release: The promoter indicated that the pledge had become excessive relative to its financing needs, prompting the unwind.

The filing includes a detailed table of all promoters and their shareholdings, both free and pledged, as of the reporting date. For Ravi Agrawal Trust, the table shows:

The release of 160,000 shares therefore reduces the pledged portion by 1.36% points of the promoter’s holding.

Shareholding impact

While the pledge has been reduced, the overall shareholding of the promoter remains unchanged at 12,792,904 shares. The only alteration is the removal of the encumbrance on 160,000 shares. No new shares were issued, transferred, or sold as part of this transaction. Consequently, the promoter’s voting power and economic interest in Ajanta Pharma are unaffected.

Key facts at a glance

Why this matters for investors

The release of pledged shares is a regulatory disclosure that informs shareholders about changes in the security interest on promoter holdings. A lower pledged proportion can be interpreted as a reduction in the risk that the promoter’s shares might be forced to be sold in the event of loan default. However, because the promoter’s total shareholding remains the same, the ownership structure and control dynamics are unchanged. Investors should note that the pledge was originally linked to a business‑financing facility; its unwind suggests that the promoter has either repaid part of the loan or re‑structured the collateral.

From a compliance perspective, the filing satisfies SEBI’s requirement for timely disclosure of any creation, release, or invocation of encumbrances on promoter shares. Failure to disclose such events could attract regulatory scrutiny, so the prompt filing reinforces Ajanta Pharma’s adherence to corporate governance norms.

Conclusion

Ajanta Pharma has formally reported that the Ravi Agrawal Trust released a pledge on 160,000 shares on 30 June 2026, bringing the total pledged shares down to 1.54 million. The promoter’s overall stake remains unchanged, and the disclosure fulfills SEBI’s SAST reporting obligations. No further actions, such as additional share transactions or board approvals, are indicated in the filing.

"The reason for release of pledge is Excess Pledge," the filing states.